Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model

Why It Matters

A one‑shot vaccine could halt transmission of the only person‑to‑person hantavirus, offering a fast‑acting tool for exposed individuals and filling a critical gap in global infectious‑disease preparedness.

Key Takeaways

• Single-dose mRNA vaccine achieved 100% protection in hamsters
• Vaccines target Andes virus envelope glycoproteins Gn and Gc
• Fast immunity observed within 14 days post‑vaccination
• Potential emergency tool for exposed high‑risk contacts
• UTMB aims to fast‑track human clinical trials

Pulse Analysis

The recent Andes virus outbreak on a Dutch cruise ship highlighted a rare but serious public‑health challenge: unlike most hantaviruses, Andes can spread efficiently between people through respiratory secretions. Thirteen infections and three deaths underscored the virus’s lethal potential, especially in confined environments where asymptomatic carriers can unknowingly transmit the pathogen for weeks. With no licensed prophylaxis, health authorities faced a daunting task of tracing contacts across multiple nations, amplifying the urgency for a rapid‑acting vaccine solution. The incident also prompted the World Health Organization to issue interim guidance on monitoring and isolation, emphasizing the need for scalable preventive tools.

University of Texas Medical Branch scientists responded by engineering two mRNA constructs that encode the Andes envelope glycoproteins Gn and Gc, using both modified and unmodified nucleoside formats. In golden Syrian hamsters, a conventional two‑dose schedule already showed robust protection, but the team pivoted to a single‑shot regimen to mimic outbreak conditions. Remarkably, even at reduced doses the vaccine delivered 100 % survival, no weight loss, and complete viral clearance within a month, with neutralizing antibodies detectable as early as 14 days. The researchers also demonstrated that the immune response was durable, with serological assays showing sustained antibody titers for at least eight weeks post‑immunization.

The data position this single‑dose mRNA platform as a potential emergency countermeasure for high‑risk exposures, allowing rapid immunization of contacts during an outbreak. If human trials confirm comparable efficacy, regulators could consider an accelerated approval pathway similar to that used for COVID‑19 boosters, opening a new market for hantavirus prophylaxis. Moreover, the success reinforces the versatility of mRNA technology beyond coronavirus vaccines, encouraging investment in rapid‑development pipelines for other zoonotic threats that lack existing countermeasures. Beyond Andes, the platform could be adapted quickly to other hantavirus species, potentially curbing future spillover events from rodent reservoirs.